本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

LAVA Therapeutics N.V.

1.51
-0.0200-1.31%
盘后1.510.00000.00%16:10 EDT
成交量:34.15万
成交额:52.08万
市值:3,972.10万
市盈率:-1.43
高:1.55
开:1.53
低:1.50
收:1.53
52周最高:2.09
52周最低:0.8502
股本:2,630.53万
流通股本:1,022.19万
量比:2.91
换手率:3.34%
股息:- -
股息率:- -
每股收益(TTM):-1.0538
每股收益(LYR):-0.9359
净资产收益率:-90.19%
总资产收益率:-21.30%
市净率:1.99
市盈率(LYR):-1.61

数据加载中...

2025/08/14

重要事件披露

Form 8-K - Current report
2025/08/13

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/08/04

重要事件披露

Form 8-K - Current report
2025/06/13

重要事件披露

Form 8-K - Current report
2025/05/23

重要事件披露

Form 8-K - Current report
2025/05/15

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/03/28

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/03/28

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/03/28

重要事件披露

Form 8-K - Current report
2025/02/28

重要事件披露

Form 8-K - Current report
2025/02/25

重要事件披露

Form 8-K - Current report
2025/01/02

重要事件披露

Form 8-K - Current report
2024/03/20

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/03/07

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/11/10

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/06/06

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/06/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/04/11

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/24

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership